B+
Bull case
25%
Probability
Target price
$11.50
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
NVAX
NovavaxDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$8.50
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$5.50
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-08
Recent news sentiment (30D)
+0.2
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+51.5
Score
AI commentary
The post-print market response was modestly positive, with NVAX at $7.95 and up about 2.6% versus the prior close, while available coverage characterized the stock as holding steady. The raised framework and lower GAAP cost outlook improved the near-term narrative, but the absence of analyst revisions, low coverage, lumpy partner revenue, and weak Q2 earnings quality support a monitoring stance rather than a high-conviction bullish call.
RankAlpha Sentiment Codex - 2026-08-08
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-06eventQ2 print raised revenue framework and reduced GAAP cost guidanceHigh impact
Novavax reported Q2 revenue of $57 million, raised its 2026 adjusted total revenue framework to $235-$275 million from $230-$270 million, and lowered GAAP combined R&D and SG&A guidance by $10 million at the midpoint. However, Q2 revenue declined 76% year over year because the prior-year period included $202 million of milestone and amendment revenue. [#8-K-2026-08-06]
2026-12-31eventSanofi CIC regulatory timing and milestone conversionHigh impact
Sanofi is in advanced discussions with regulators regarding timing for its Phase 3 COVID-19-influenza combination trial. Trial initiation in the U.S. or EU would trigger a $125 million milestone, while manufacturing technology transfer expected in mid-2027 could trigger another $75 million milestone; timing remains unconfirmed and partner-controlled. [#8-K-2026-08-06]
2027-12-31catalystMatrix-M partnering and C. difficile development optionalityHigh impact
Multiple partner-led Matrix-M experiments are underway across infectious-disease and oncology targets, while Novavax has advanced its C. difficile candidate into pre-IND interactions and GMP manufacturing with potential clinical entry as early as 2027. Commercial conversion and clinical timing remain uncertain. [#8-K-2026-08-06]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-08 • Updated nightlySource: Internal modelMethodology